Nothing Special   »   [go: up one dir, main page]

Schmitz et al., 2002 - Google Patents

Quantification of antigen‐reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells

Schmitz et al., 2002

View PDF
Document ID
2904224817247323245
Author
Schmitz M
Rohayem J
Paul R
Weigle B
Stein A
Rieber E
Publication year
Publication venue
Journal of clinical laboratory analysis

External Links

Snippet

The enzyme‐linked immunospot (ELISPOT) assay has become a widely employed method for quantification of antigen‐reactive T lymphocytes. In recent years, various types of antigen‐ presenting cells (APCs) have been tested as stimulator cells in ELISPOT protocols to …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Similar Documents

Publication Publication Date Title
Peshwa et al. Induction of prostate tumor‐specific CD8+ cytotoxic T‐lymphocytes in vitro using antigen‐presenting cells pulsed with prostatic acid phosphatase peptide
Panelli et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
Zom et al. TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients
Asai et al. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines
BenMohamed et al. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity
Mailliard et al. Complementary dendritic cell–activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses
Butterfield et al. Adenovirus MART-1–engineered autologous dendritic cell vaccine for metastatic melanoma
Josien et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
US6077519A (en) Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
Kuzushima et al. Tetramer-assisted identification and characterization of epitopes recognized by HLA A* 2402–restricted Epstein-Barr virus–specific CD8+ T cells
Schumacher et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses
WO2007049737A1 (en) Cytotoxic t-cell epitope peptide capable of specifically attacking cell infected with epstein-barr virus
JP6401342B2 (en) Antigenic peptide derived from T790M point mutation sequence of epidermal growth factor receptor
WO2016203577A1 (en) Cytotoxic t-cell epitope peptide and use thereof
KR20100028074A (en) Cytotoxic t lymphocyte
WO2007015540A1 (en) Cytotoxic t-cell epitope peptide and use thereof
Salgaller et al. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide
Kaka et al. Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale
Wong et al. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma
JP2005512517A (en) Inducible Hsp70-derived polypeptide and pharmaceutical composition containing this polypeptide
Klyushnenkova et al. CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis
Kather et al. Identification of a naturally processed HLA‐A* 0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination
Kobayashi et al. A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope
WO2017086354A1 (en) Hla-a11 restrictive cytotoxic t cell epitope peptide
Schmitz et al. Quantification of antigen‐reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells